Semaglutide dosage reference: typical range 0.25 – 2.4 mg, 1× per week (same day), cycle Continuous (titrate up over months); 4-week titration phases…
FDA-approved GLP-1 agonist that has transformed weight loss medicine. Mimics glucagon-like peptide-1 to reduce appetite, slow gastric emptying, and improve insulin sensitivity.
Published protocol literature for Semaglutide describes a typical range of 0.25 – 2.4 mg, dosed 1× per week (same day), over a cycle of Continuous (titrate up over months); 4-week titration phases. Reported half-life: approximately 7 days.
| Parameter | Reported value |
|---|---|
| Typical dose range | 0.25 – 2.4 mg |
| Frequency | 1× per week (same day) |
| Cycle length | Continuous (titrate up over months); 4-week titration phases |
| Half-life | Approximately 7 days |
| Route | Subcutaneous injection (most published protocols) |
| Diluent | Bacteriostatic water |
| Commonly stacked with | AOD-9604 (synergistic lipolysis), Tesamorelin (muscle preservation) |
Protocols are usually titrated rather than started at the top of the range. The tiers below reflect how Semaglutide dosing is commonly stepped in the published protocol literature.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 0.25 mg | Weekly (same day) | Titration phase; mild nausea expected |
| Intermediate | 0.5–1.0 mg | Weekly | Steady weight loss 1–2 lbs/week |
| Advanced | 1.7–2.4 mg | Weekly | Maximum dose; manage GI side effects |
Concentration in mcg/mL equals vial milligrams multiplied by 1000, divided by the millilitres of bacteriostatic water added. Volume per dose in mL equals the target dose in mcg divided by that concentration. On a U-100 insulin syringe, multiply the volume in mL by 100 to read the units.
| Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|
| 2 mg vial | 1 mL bacteriostatic water | 2,000 mcg/mL |
| 5 mg vial | 2 mL bacteriostatic water | 2,500 mcg/mL |
| 10 mg vial | 2 mL bacteriostatic water | 5,000 mcg/mL |
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
Dose ranges on this page summarise published research and practitioner protocol literature for Semaglutide. They are a reference, not medical direction. All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Published protocol literature for Semaglutide generally describes 0.25 – 2.4 mg, administered 1× per week (same day). Individual protocols vary and should be set by a licensed practitioner.
1× per week (same day). Frequency is driven by half-life — Semaglutide has a reported half-life of approximately 7 days, so shorter-acting compounds are dosed more often.
Typical cycle length reported is Continuous (titrate up over months); 4-week titration phases. Cycling exists to limit receptor desensitisation and to create assessment windows, not as a fixed rule.
2mg → 1ml bacteriostatic water; 5mg → 2ml bacteriostatic water; 10mg → 2ml bacteriostatic water. Concentration in mcg/mL equals vial milligrams times 1000 divided by millilitres of bacteriostatic water.
Semaglutide targets the GLP-1 receptor alone. Tirzepatide is a dual GIP/GLP-1 receptor agonist, hitting two incretin pathways at once.
Yes. Any clinical use must be directed by a licensed medical practitioner. Research-use product is supplied for investigational purposes only.